Numinus files international patent application for psychedelic manufacturing process

Filing would provide additional protection to IP already submitted to USPTO

VANCOUVER, BCJune 22, 2022 /PRNewswire/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health company that promotes innovative treatments and safe, evidence-based therapies involving psychedelics, today announced that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a patent application with the World Intellectual Property Organization (WIPO), a United Nations agency, for a rapid manufacturing process for: psilocybe and other fungi containing psilocybin and other compounds.

A preliminary patent application for the process has been filed with the United States Patent & Trademark Office (USPTO) on June 24, 2021† With this additional application, international patent protection would extend to all WIPO member states that have signed the Patent Cooperation Treaty (PCT), including AustraliaGermanyThe Netherlands and the United Kingdomwhere psychedelic research is currently active.

“WIPO is an important global forum that reassures member state patent offices. Numinus is confident that the robust evidence supporting the manufacturing process will further inform regulators as they consider policy changes to make psychedelic-assisted therapies and products more accessible, ” said Sharan Sidhu, VP, Scientific Research, Innovation and Laboratory Activities, Numinus. “We look forward to advancing current research and paving the way for eventual commercialization and mainstream access.”

The goal of the process is to significantly increase the production of therapies for use in psychedelic therapy while reducing product variability, increasing production efficiency and ultimately reducing commercialization costs. Since the first submission, data sets validating the process for additional fungal specifications have been completed, expanding the potential application and scope of psilocybin to other active compounds.

“This application is part of Numinus’ strategic focus on long-term IP on scalable and sustainable manufacturing that advances the research, development and delivery of innovative psychedelic-derived formulations in North America and beyond,” said Payton NyquvestFounder and CEO, Numinus.

About Numinus

Numinus Wellness helps people heal and become healthy through the development and delivery of innovative mental health services and access to safe, evidence-based psychedelic therapies. The Numinus model – including psychedelic production, research and clinical care – is at the forefront of a transformation that focuses on healing rather than managing symptoms of depression, anxiety, trauma, pain and substance use. At Numinus, we lead the integration of psychedelic therapies into mainstream clinical practice and lay the foundation for a healthier society.

More information on numinus.com and follow us LinkedInfacebookTwitterand Instagram

Disclaimer

Neither Numinus Wellness Inc. nor any of its subsidiaries is a professional corporation licensed to perform health services. In jurisdictions where health services may only be provided by a business if that business is validly licensed to do so, Numinus and its subsidiaries operate in a management services function for affiliated professional companies, providing health services to patients. Numinus and its subsidiaries provide health services directly to patients in those jurisdictions where they are authorized to do so.

Forward-Looking Statements

Statements and other information in this press release about anticipated future events are forward-looking statements. Forward-looking statements are often, but not always, identified through the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” and “intend” and statements that an event “may”, “will”, “would”, “could”, or “might” occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those in the forward-looking statements. Forward-looking statements are based on management’s estimates and opinions as of the date on which the statements are made. The company assumes no obligation to update any forward-looking statements, even if circumstances or management’s estimates or opinions should change, except as required by applicable law. Investors should not place undue reliance on forward-looking statements.

decision

decision

View original content:https://www.prnewswire.com/news-releases/numinus-applies-for-international-patent-filing-of-psychedelics-production-process-301572540.html

SOURCE Numinus Wellness Inc.

Leave a Comment

Your email address will not be published.